We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aurora Signs Agreement with Alion Pharmaceuticals and Specs

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aurora Signs Agreement with Alion Pharmaceuticals and Specs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Aurora Biomed Inc. has announced that it has signed an agreement with Alion Pharmaceuticals and Specs to form a new Ion Channel Consortium that will provide a novel, comprehensive solution for ion channel drug discovery.

Together, the three companies will offer value added identification and validation of ion channel modulators.

The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s superior patch clamp services.

Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channelopathies.